- Home
- PDS vs AUPH Comparison
PDS vs AUPH Comparison
Compare PDS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDS | AUPH |
|---|---|---|
| Founded | 1951 | 1993 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | PDS | AUPH |
|---|---|---|
| Price | $70.47 | $15.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $99.00 | $17.25 |
| AVG Volume (30 Days) | 87.7K | ★ 1.1M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.98 | 0.55 |
| Revenue | ★ $1,316,232,437.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | $2.89 | $16.45 |
| P/E Ratio | ★ $22.39 | $28.07 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $36.20 | $6.55 |
| 52 Week High | $75.25 | $16.54 |
Technical Indicators
Market Signals| Indicator | PDS | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 56.02 |
| Support Level | $68.85 | $14.82 |
| Resistance Level | $75.25 | $15.98 |
| Average True Range (ATR) | 2.04 | 0.42 |
| MACD | -0.23 | -0.11 |
| Stochastic Oscillator | 38.08 | 68.02 |
Price Performance
Historical ComparisonAbout PDS Precision Drilling Corporation
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.